Electronics
Computer Hardware
Cancer Prevention
iCAD
$6.349876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$6.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.26 (4.28%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell iCAD and other stocks, options, ETFs, and crypto commission-free!
About
iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. It operates through the Cancer Detection and Cancer Therapy business segments. Read More The Cancer Detection segment includes image analysis and clinical decision support solutions for mammography, breast tomosynthesis, and computed tomography imaging. The Cancer Therapy segment offers an isotope-free cancer treatment platform technology. The company was founded in 1984 and is headquartered in Nashua, NH.
Employees
97
Headquarters
Nashua, New Hampshire
Founded
1984
Market Cap
109.77M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
96.09K
High Today
$6.40
Low Today
$5.91
Open Price
$6.19
Volume
62.38K
52 Week High
$6.45
52 Week Low
$2.43
Collections
Electronics
Computer Hardware
Cancer Prevention
Therapy
Medical
Technology
Health
US
News
Yahoo FinanceMay 15
ICAD: Therapy Buoys Q1 Sales, Benefits Operating Loss. Detection Acceleration Still Expected in 2H
By Brian Marckx, CFA NASDAQ:ICAD READ THE FULL ICAD RESEARCH REPORT Q1 2019 Results: Therapy Buoys Q1 Sales, Benefits Operating Loss. Detection Acceleration Still Expected in 2H… iCAD (ICAD) reported financial results for their first quarter and provided a business update. As it relates to the financials, revenue was relatively very strong, particularly as compared to our estimates, up 7% yoy and down just 3% on a sequential basis. The low single-digit qoq contraction is notably encouraging give...
Seeking AlphaMay 10
iCAD's CEO Michael Klein on Q1 2019 Results - Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Jeremy Feffer – Investor Relations Michael Klein – Chairman and Chief Executive Officer Scott Areglado – Chief Financial Officer Stacey Stevens – President Conference Call Participants Per Ostlund – Craig-Hallum Capital Group Francoise Brisebois – Laidlaw Brian Marckx – Zacks Investment Research Operator Greetings. Welcome to the iCAD, Inc. First Quarter 2019 Earnings Conference Call. [Operator I...
Yahoo FinanceMay 7
Analysts Expect Breakeven For iCAD, Inc. (NASDAQ:ICAD)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! iCAD, Inc.'s (NASDAQ:ICAD): iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. On 31 December 2018, the US$92m market-cap posted a loss of -US$9.0m for its most recent financial year. The most pressing concern for investors is ICAD’s path to profitability – when wi...
Price Paid on Robinhood
40% Higher
Right Now
52 Week Low
$2.43
Average Price Paid
$4.52
52 Week High
$6.45
Earnings
-$0.19
-$0.15
-$0.10
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 13, Pre-Market